Irritable Bowel Syndrome (IBS) Diagnostics Market is expected to reach US$ 3,880.91 million by 2028

Published Date: 31 Mar 2021

Report : Irritable Bowel Syndrome (IBS) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Diagnosis (Laboratory Tests, Imaging Tests); Indication (Pain and Cramping, Diarrhea, Constipation, Alternating Constipation and Diarrhea), and Geography

Increasing Prevalence of Irritable Bowel Syndrome and Associated Conditions Drive Irritable Bowel Syndrome (IBS) Diagnostics Market

 

According to The Insight Partners market research study titled “Irritable Bowel Syndrome (IBS) Diagnostics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Diagnosis and Indication ,” the market is expected to reach US$ 3,880.91 million by 2028 from US$ 2,470.61 million in 2020; it is estimated to grow at a CAGR of 5.9% from 2020 to 2028. The report highlights the trends prevailing in the global irritable bowel syndrome (IBS) diagnostics market, along with market drivers and deterrents.

 

Based on diagnosis, the global irritable bowel syndrome (IBS) diagnostics market is segmented into laboratory tests and imaging tests. In 2020, the laboratory tests segment held the largest share in the market. Moreover, the segment is expected to hold the largest market share by 2028. The market growth is mainly attributed to the growing prevalence of irritable bowel syndrome (IBS) worldwide, which is likely to continue in the coming years due to disturbances in bowel habits and abdominal pain. This, in turn, is boosting the demand for diagnosis of these diseases worldwide.

 

Increasing prevalence of irritable bowel syndrome and associated conditions and increasing number of FDA approvals and diagnostics developments are driving the global irritable bowel syndrome (IBS) diagnostics market. However, the challenges in diagnosis of IBS are limiting the market growth.

                                                                                                                       

The COVID-19 pandemic is estimated to have a significant positive impact on the irritable bowel syndrome (IBS) diagnostics market. Majority of the pharmaceutical companies across the world are engaged in the development of vaccines for COVID-19. Moreover, irritable bowel syndrome (IBS) is frequently triggered by COVID-19 stress. Thus, home testing kits are preferable to laboratory testing as laboratory services may be overwhelmed in the pandemic, which is anticipated to have a positive impact on the other segments of the market in the coming months. However, disruptions in the supply chain caused due to the halt in global operations are hindering the market growth.  

 

A few prominent players operating in the irritable bowel syndrome (IBS) diagnostics market are Commonwealth Diagnostics International; Genova Diagnostics; Gemelli Biotech; Prometheus Laboratories; Inova Diagnostics, Inc.; Biohit Oyj; Aerodiagnostics, LLC.; Metabolic Solutions, Inc.; Sysmex Corporation; and Bühlmann Laboratories AG, among others.

 

Market players are introducing new and innovative products and services to sustain their position in the irritable bowel syndrome (IBS) diagnostics market. For instance, in February 2020, Commonwealth Diagnostics International (CDI), Inc. announced the commercial re-launch of IBSchek, the first clinically validated biomarker blood test for diarrhea-predominant and mixed-type irritable bowel syndrome (IBS-D, IBS-M) in a new at-home capillary collection kit.


Irritable Bowel Syndrome (IBS) Diagnostics Market, by Region, 2020 (%)        


 Irritable Bowel Syndrome (IBS) Diagnostics Market, by Region, 2020 (%)         

 

The report segments the global irritable bowel syndrome (IBS) diagnostics market as follows:

 

Irritable Bowel Syndrome (IBS) Diagnostics Market – by Diagnosis

  • Laboratory Tests
    • Lactose Intolerance Tests
    • Breath Test for Bacterial Overgrowth
    • Stool Tests
    • Blood Tests
  • Imaging Tests
    • CT Scan or X-Ray
    • Upper Endoscopy
    • Colonoscopy

 
Irritable Bowel Syndrome (IBS) Diagnostics Market – by Indication

  • Pain and Cramping
  • Diarrhea
  • Constipation
  • Alternating Constipation and Diarrhea


 Irritable Bowel Syndrome (IBS) Diagnostics Market – by Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Middle East & Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Rest of Middle East & Africa
  • South and Central America (SCAM)
    • Brazil
    • Argentina
    • Rest of South and Central America

Contact Us
Contact Person: Sameer Joshi 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com     
Download Free PDF Brochure